We expect the slow market to continue to impact Etteplan in 2024, while acquisitions support net sal...
Redeye comments on SenzaGen’s directed issue, raising SEK37.
We initiate coverage of Solwers, a company that acts as a growth platform for the built environment ...
Redeye makes a few comments following last week's hearing in Aequitas' patent lawsuit, which involve...
CirChem (”CirChem” eller ”Bolaget”) meddelade den 12 juni 2024 att Bolaget, efter ett framgångsrikt ...
Eastnine förvärvar en andra fastighet i polska Poznan och ökar hyresintäkterna med drygt 16% till 42...
Redeye provides a brief comment on the subscription rate of Lipigon's warrant TO3.
Redeye comments on recent news from Flexion Mobile, which has finally filed its delayed 2022 account...
PMD is expanding in the UK, Germany and the US, and as a result, the company is proposing a rights i...
Redeye comments on the news that Moberg Pharma has secured the exercise of warrants and entered into...
Redeye sees a positive press release from Lifecare confirming that the company has managed to improv...
Weakness seen in Q1 has continued in Q2 leading Scanfil to downgrade its full year net sales guidanc...
Unique investment company that compares favourably to peers High exposure to private assets NAV disc...
Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) är en modern spelkoncern beståe...
We had a chat with Justin Pierce, CEO of the Magle Group, and Marcus Larsson, CEO of Amniotics, abou...
